LIFE Stock - Lifeline Systems, Inc.

LIFE Stock Chart

LIFE Profile

aTyr Pharma, Inc. is a pioneering biotherapeutics company focused on advancing medicines derived from innovative immunological pathways within the United States. The company's primary focus lies in the discovery and development of novel therapies that target specific immunological mechanisms. Leading its pipeline is efzofitimod, a selective modulator of NRP2 currently undergoing Phase II clinical trials for pulmonary sarcoidosis, with additional Phase 1b/2a trials for treating various interstitial lung diseases (ILDs) including chronic hypersensitivity pneumonitis and connective tissue disease related ILD. In parallel, aTyr Pharma is advancing ATYR2810, a fully humanized monoclonal antibody in preclinical stages, aimed at treating solid tumors.

In pursuit of its mission, aTyr Pharma has forged strategic collaborations such as the partnership with Kyorin Pharmaceutical Co., Ltd., which focuses on the development and commercialization of efzofitimod specifically for ILDs within the Japanese market. These collaborations bolster the company's efforts to expand its therapeutic footprint globally while advancing the forefront of biotechnology innovation. Founded in 2005 and headquartered in San Diego, California, aTyr Pharma continues to leverage its deep expertise and commitment to addressing unmet medical needs through groundbreaking research and development initiatives in immunology.

The company's robust portfolio and strategic alliances underscore its dedication to transforming patient outcomes in critical therapeutic areas. With a strong foundation in biopharmaceutical research, aTyr Pharma is poised to make significant strides in enhancing treatment options and improving quality of life for patients facing challenging immunological disorders and cancers.

LIFE Revenue Chart

LIFE Earnings

Analyst Ratings